Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: October 11, 2006
Last updated: July 26, 2012
Last verified: May 2012
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.

Condition Intervention Phase
Migraine, Without Aura
Drug: sumatriptan succinate / naproxen sodium
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET)

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose. [ Time Frame: 2 hours through 24 hours after Treatment ] [ Designated as safety issue: No ]
    Pain-free was defined as a headache severity of no pain (grade 0) at 2 hours post-treatment in subjects who have not used rescue medication prior to or at the time of the assessment. Sustained pain-free response was defined as pain-free at 2 hours post-treatment through 24 hours post-treatment without rescue medicine.

Secondary Outcome Measures:
  • Freedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment [ Time Frame: 0.5, 1, and 4 hours after Treatment ] [ Designated as safety issue: No ]
    Pain-Free is defined as post-treatment headache pain severity of none in subjects who have not used rescue medication prior to or at the time of the assessment.

  • Sustained Headache Relief 2-24 Hours After Treatment [ Time Frame: 2-24 hours after treatment ] [ Designated as safety issue: No ]
    Sustained pain relief was defined as having pain relief (mild or no pain) at 2 hours w/o any moderate or severe pain during 2-24 hour period post-treatment, without rescue medication.

  • Headache Relief at 4, 2, 1 and 0.5 Hours After Treatment [ Time Frame: 0.5, 1, 2, and 4 hours after treatment ] [ Designated as safety issue: No ]
    Pain relief was defined as reduction of headache pain from a baseline severity of moderate or severe to none or mild at the given time.

  • Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment [ Time Frame: 0 - 24 hours after treatment ] [ Designated as safety issue: No ]
    Rescue medication defined as additional medication (i.e. sumatriptan/naproxen sodium as open-label rescue or other medication as permitted per protocol), taken by subject for the treatment of headache pain or other symptoms associated with the headache attack.

  • Intermediate Sustained Pain Relief: Post-dose at Intervals of 2-4 Hours and 1-2 Hours After Treatment [ Time Frame: 1-2, and 2- 4 hours after treatment ] [ Designated as safety issue: No ]
    Intermediate sustained pain relief was defined as achieving headache pain relief (from moderate or severe pain at baseline to mild or no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours). (Intermediate=Intermed.)

  • Intermediate Sustained Pain-Free: Post-dose at Intervals of 2-4 Hours and 1-2 Hours [ Time Frame: 1-2 and 2-4 hours after treatment ] [ Designated as safety issue: No ]
    Intermediate sustained pain free was defined as achieving headache pain-free (moderate or severe pain to no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours).(Intermediate=Intermed.)

  • Incidence of Headache Associated: Neck Pain, Sinus Pain, Photophobia, Phonophobia, Nausea at Time Intervals of 4 and 2 Hours After Treatment [ Time Frame: 2 and 4 hours after treatment ] [ Designated as safety issue: No ]
    Neck pain, sinus pain, photophobia, phonophobia and nausea are considered headache-associated symptoms.(Headache-associated=Headache-Assoc.)

  • Medication Satisfaction: Mean Patient Perception of Migraine (PPMQ-R) Subscale Score [ Time Frame: 0 - 24 hours after treatment ] [ Designated as safety issue: No ]
    Patient Perception of Migraine Questionnaire-Revised(PPMQ-R) evaluates subject satisfaction with treatment 24 hours post-dose using validated questions. Questions are analyzed on 4 subscale scores (efficacy, functionality, ease-of-use, and tolerability) and total score. Scores range from 0-100, with the higher scores indicating better satisfaction.

Enrollment: 679
Study Start Date: September 2006
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo to match Treximet tablets
Experimental: Treximet Drug: sumatriptan succinate / naproxen sodium
sumatriptan 85mg / naproxen sodium 500mg


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least a 6 month history of probably migraine (6 migraine attacks per month)
  • Males and women of childbearing potential on a adequate contraception.

Exclusion Criteria:

  • Physician diagnosis of migraine; history of triptan or ergot use; history of headache prophylaxis use
  • Pregnant and/or nursing mother
  • History of cardiovascular disease.
  • Uncontrolled hypertension.
  • Basilar or Hemiplegic migraine
  • History of stroke or transient ischemic attacks (TIA).
  • History of epilepsy or treated with anti-epileptics within the past 5 years.
  • Impaired hepatic or renal function.
  • History of gastrointestinal bleeding or ulceration.
  • Allergy or hypersensitivity to Aspirin or any other NSAID.
  • Allergy or hypersensitivity to triptans.
  • Participated in an investigational drug trial in the previous 4 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00387881

  Hide Study Locations
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85014
GSK Investigational Site
Phoenix, Arizona, United States, 85050
United States, Arkansas
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
GSK Investigational Site
Anaheim, California, United States, 92801
GSK Investigational Site
Anaheim, California, United States, 92805
GSK Investigational Site
Buena Park, California, United States, 90620
GSK Investigational Site
Diamond Bar, California, United States, 91765
GSK Investigational Site
Newport Beach, California, United States, 92660
GSK Investigational Site
San Diego, California, United States, 92128
GSK Investigational Site
San Francisco, California, United States, 94109
GSK Investigational Site
Santa Monica, California, United States, 90404
GSK Investigational Site
Walnut Creek, California, United States, 94596
GSK Investigational Site
Westlake Village, California, United States, 91361
United States, Colorado
GSK Investigational Site
Colorado Springs, Colorado, United States, 80904
United States, Connecticut
GSK Investigational Site
Stamford, Connecticut, United States, 06902
United States, Florida
GSK Investigational Site
Miami, Florida, United States, 331144
GSK Investigational Site
Pembroke Pines, Florida, United States, 33024
GSK Investigational Site
West Palm Beach, Florida, United States, 33407
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30033
GSK Investigational Site
Atlanta, Georgia, United States, 30308
GSK Investigational Site
Atlanta, Georgia, United States, 30342
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60614
United States, Indiana
GSK Investigational Site
Evansville, Indiana, United States, 47712
United States, Kansas
GSK Investigational Site
Wichita, Kansas, United States, 67207
United States, Louisiana
GSK Investigational Site
New Orleans, Louisiana, United States, 70121
United States, Massachusetts
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48104
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
United States, Minnesota
GSK Investigational Site
St. Louis Park, Minnesota, United States, 55426
United States, Missouri
GSK Investigational Site
Springfield, Missouri, United States, 65804
GSK Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89146
United States, New Mexico
GSK Investigational Site
Albuquerque, New Mexico, United States, 87108
United States, New York
GSK Investigational Site
Albany, New York, United States, 12206
GSK Investigational Site
Bronx, New York, United States, 10461
GSK Investigational Site
New York, New York, United States, 10022
GSK Investigational Site
Rochester, New York, United States, 14642
GSK Investigational Site
Valley Stream, New York, United States, 11580
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
GSK Investigational Site
Greensboro, North Carolina, United States, 27401
GSK Investigational Site
Raleigh, North Carolina, United States, 27609
United States, Ohio
GSK Investigational Site
Cincinnati, Ohio, United States, 45245
GSK Investigational Site
Cleveland, Ohio, United States, 44195
GSK Investigational Site
Independence, Ohio, United States, 44131
GSK Investigational Site
West Chester, Ohio, United States, 45069
GSK Investigational Site
Westerville, Ohio, United States, 43081
United States, Oregon
GSK Investigational Site
Medford, Oregon, United States, 97504-8456
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107-2568
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15236
United States, South Carolina
GSK Investigational Site
Anderson, South Carolina, United States, 29621
GSK Investigational Site
Simpsonville, South Carolina, United States, 29681
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78705
GSK Investigational Site
Austin, Texas, United States, 78745
GSK Investigational Site
Bellaire, Texas, United States, 77401
GSK Investigational Site
Katy, Texas, United States, 77450
GSK Investigational Site
Richardson, Texas, United States, 75080
GSK Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
GSK Investigational Site
Salt Lake City, Utah, United States, 84109
GSK Investigational Site
Salt Lake City, Utah, United States, 84121
GSK Investigational Site
West Jordan, Utah, United States, 84084
United States, Virginia
GSK Investigational Site
Alexandria, Virginia, United States, 22311
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98104
GSK Investigational Site
Seattle, Washington, United States, 98195
GSK Investigational Site
Wenatchee, Washington, United States, 98801
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53209-0996
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Silberstein S, Lipton RB, Goldstein J, Aurora SK, White J, Ochs-Ross R, Lener SE, McDonald SA. Evaluation of a New Fixed-dose Single Tablet of Sumatriptan Formulated with RT Technology and Naproxen Sodium (SumaRT/Nap) for the Acute Treatment of Probable Migraine without Aura. Headache 2008: presented at the American Headache Society Meeting, Boston, MA.

Responsible Party: GlaxoSmithKline Identifier: NCT00387881     History of Changes
Other Study ID Numbers: TXA107563 
Study First Received: October 11, 2006
Results First Received: February 19, 2009
Last Updated: July 26, 2012
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
sumatriptan succinate,
naproxen sodium,
parallel group,
Combination product,
migrainous headache
Probable migraine, a sub-type of Migraine
probable migraine,

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents processed this record on December 07, 2016